These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 26589767)

  • 1. Identification of Anti-CA125 Antibody Responses in Ovarian Cancer Patients by a Novel Deep Sequence-Coupled Biopanning Platform.
    Frietze KM; Roden RB; Lee JH; Shi Y; Peabody DS; Chackerian B
    Cancer Immunol Res; 2016 Feb; 4(2):157-64. PubMed ID: 26589767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virus-like particle vaccine displaying an external, membrane adjacent MUC16 epitope elicits ovarian cancer-reactive antibodies.
    Tu HF; Wong M; Tseng SH; Ingavat N; Olczak P; Notarte KI; Hung CF; Roden RBS
    J Ovarian Res; 2024 Jan; 17(1):19. PubMed ID: 38225646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125.
    Wagner U; Schlebusch H; Köhler S; Schmolling J; Grünn U; Krebs D
    Hybridoma; 1997 Feb; 16(1):33-40. PubMed ID: 9085126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved soluble expression of a single-chain antibody fragment in E. coli for targeting CA125 in epithelial ovarian cancer.
    Sharma SK; Suresh MR; Wuest FR
    Protein Expr Purif; 2014 Oct; 102():27-37. PubMed ID: 25079010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human monoclonal antibody for ovarian clear cell carcinoma-2, a human monoclonal antibody with antitumor activity against ovarian cancer cells that recognizes CA125-like antigen.
    Suzuki N; Tamada Y; Shigirahara K; Suzuki A; Susumu N; Ishida I; Aoki D
    Int J Gynecol Cancer; 2008; 18(5):996-1006. PubMed ID: 18028379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional mimicry of an anti-idiotypic antibody to nominal antigen on cellular response.
    Ma J; Zhou L; Wang D
    Jpn J Cancer Res; 2002 Jan; 93(1):78-84. PubMed ID: 11802811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival-a substudy of the MIMOSA trial.
    Buzzonetti A; Fossati M; Catzola V; Scambia G; Fattorossi A; Battaglia A
    Cancer Immunol Immunother; 2014 Oct; 63(10):1037-45. PubMed ID: 24952307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13--evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo.
    Noujaim AA; Schultes BC; Baum RP; Madiyalakan R
    Cancer Biother Radiopharm; 2001 Jun; 16(3):187-203. PubMed ID: 11471484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
    Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
    Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer identifies a lead candidate for clinical translation.
    Nemieboka B; Sharma SK; Rao TD; Edwards KJ; Yan S; Wang P; Ragupathi A; Piersigilli A; Spriggs DR; Lewis JS
    Nucl Med Biol; 2020; 86-87():9-19. PubMed ID: 32403071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a Mu-9 (anti-colon-specific antigen-p)-reactive peptide having homology to CA125 (MUC16).
    Modrak DE; Karacay H; Cardillo TM; Newsome G; Goldenberg DM; Gold DV
    Int J Oncol; 2005 Jun; 26(6):1591-6. PubMed ID: 15870874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
    Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
    Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of a novel microscopic technique for quantifying CA125 binding to circulating mononuclear cells in longitudinal specimens during treatment for ovarian cancer.
    Lakatos K; González G; Hoballah J; Brooker J; Jeong S; Evans C; Krauledat P; Hansen WP; Elias KM; Patankar M; Fülöp V; Konstantinopoulos PA; Cramer DW
    J Ovarian Res; 2022 Feb; 15(1):28. PubMed ID: 35219339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients.
    Gordon AN; Schultes BC; Gallion H; Edwards R; Whiteside TL; Cermak JM; Nicodemus CF
    Gynecol Oncol; 2004 Aug; 94(2):340-51. PubMed ID: 15297171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2009 Jan; 200(1):75.e1-10. PubMed ID: 18976739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre.
    Osman N; O'Leary N; Mulcahy E; Barrett N; Wallis F; Hickey K; Gupta R
    Ir Med J; 2008 Sep; 101(8):245-7. PubMed ID: 18990955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of human ovarian carcinoma with OvaRex MAb-B43.13 in a human-PBL-SCID/BG mouse model.
    Schultes BC; Zhang C; Xue LY; Noujaim AA; Madiyalakan R
    Hybridoma; 1999 Feb; 18(1):47-55. PubMed ID: 10211788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CA125 immune complexes in ovarian cancer patients with low CA125 concentrations.
    Cramer DW; O'Rourke DJ; Vitonis AF; Matulonis UA; Dijohnson DA; Sluss PM; Crum CP; Liu BC
    Clin Chem; 2010 Dec; 56(12):1889-92. PubMed ID: 20943848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.
    Felder M; Kapur A; Gonzalez-Bosquet J; Horibata S; Heintz J; Albrecht R; Fass L; Kaur J; Hu K; Shojaei H; Whelan RJ; Patankar MS
    Mol Cancer; 2014 May; 13():129. PubMed ID: 24886523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and characterization of carboxy-terminus specific monoclonal antibodies for understanding MUC16 cleavage in human ovarian cancer.
    Aithal A; Junker WM; Kshirsagar P; Das S; Kaur S; Orzechowski C; Gautam SK; Jahan R; Sheinin YM; Lakshmanan I; Ponnusamy MP; Batra SK; Jain M
    PLoS One; 2018; 13(4):e0193907. PubMed ID: 29708979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.